MRI成像对肾上腺高密度肿瘤的应用价值

目的 探讨3T MRI化学位移成像(CSI)和扩散加权成像(DWI)对肾上腺高密度病变的应用价值.方法 回顾性分析48例患者61个CT值大于10HU的肾上腺高密度病变CSI及DWI成像,对肾上腺肿块同反相位的信号衰减值(SII)、肾上腺肿块-脾脏信号比(ASR)、表观扩散系数(ADC)值行散点图分析.采用SPSS 11.5进行统计学分析,并通过ROC曲线确定最佳诊断阈值、敏感性、特异性.结果 23个良性嗜铬细胞瘤,CSI信号衰减SII平均为3.73％;ASR平均为0.97,病变实性部分ADC值平均为(1.17×103)mm2/s.20个高密度腺瘤CSI示信号衰减SII平均为34.48％;ASR平均0.70,ADC值平均(1.08×103)mm2/s.13例恶性肿瘤CSI信号衰减SII为16.58％;ASR为0.96,ADC值为(0.88×10-3)mm2/s.良恶性病变间ADC值有明显统计学差异(P=0.002＜0.05),以ADC值小于0.99为标准,诊断高密度腺瘤的敏感性为70.8％,特异性为84.6％.高密度腺瘤的SII及ASR与其它高密度肿瘤有明显统计学差异,嗜铬细胞瘤的SII及ASR与其它高密度肿瘤有明显统计学差异.结论 CSI可有助于鉴别高密度腺瘤、嗜铬细胞瘤和恶性肿瘤;但无法鉴别嗜铬细胞瘤和恶性肿瘤.ADC值可有助于鉴别病变的良恶性.     

平衡稳态自由进动反相位成像序列在上腹部含脂病变中的初步应用

目的 探讨平衡稳态自由进动(B-SSFP)反相位成像序列在上腹部含脂病变诊断中的作用.资料与方法 对55例上腹部脏器患有含脂局灶病变的病例(其中局灶性脂肪肝6例、脂肪变性的肝细胞腺瘤2例、脂肪变性的肝细胞癌17例、肾上腺腺瘤16例、肾脏血管平滑肌脂肪瘤14例)进行扰相梯度回波(SPGR)T1WI同/反相位成像及B-SSFP反相位成像,分析病灶在各序列上的信号变化.结果 所有的含脂病变在SPGR T1WI反相位图像及B-SSFP反相位图像上均出现类似的信号衰减.结论 与SPGR反相位成像相比,B-SSFP反相位成像在检测病灶内脂肪方面可以提供相似的有效信息.B-SSFP序列具有用于上腹部化学位移成像的潜力.     

3.0T MR化学位移成像在常见腹部肿瘤诊断中的临床应用价值

目的探讨3.0T MR化学位移成像技术对常见腹部肿瘤诊断中的临床应用价值。方法回顾分析我院2012年11月以来36例肝癌、肾癌、肾上腺腺瘤、髓样脂肪瘤、肾血管平滑肌脂肪瘤患者的化学位移成像表现。结果 36例均在化学位移反相位上出现不同程度的信号减低或出现"勾边效应"。结论 MR化学位移成像在常见腹部肿瘤诊断中具有实际临床价值。     

垂体微腺瘤MRI诊断(附25例分析)

目的：探讨和总结25例垂体微腺瘤的磁共振成像（MRI）表现。方法：对25例经MRI平扫：冠状位于SE序列T2加权成像（T2WI）、FFE序列T1加权成像（T1WI）,及行Gd-DTPA增强扫描：冠状位下FFE序列T1WI、矢状位下FFE序列T1WI检查,经手术切除得到病理证实的病例进行分析,其中7例行动态增强和延迟扫描。结果：25例垂体微腺瘤均位于垂体前叶,单发19例,其中14例位于垂体右侧部,多发6例。MRI平扫24例（T1WI）为低或稍低信号、1例为高或稍高信号;23例（T2WI）为高或稍高信号,但2例为等或稍低信号,增强后即刻扫描25例均为低或稍低信号,7例动态增强扫描延迟25－30min后1例有明显强化。结论：垂体微腺瘤MRI表现有一定特征性,MRI对诊断垂体微腺瘤有较大价值。     

菲立磁增强MRI在肝脏局灶性病变诊断中的价值

目的 评价菲立磁增强MRI在肝脏实性占位性病变诊断中的应用价值。材料与方法 对21例怀疑有肝脏局灶性占位病变患者行MR平行及菲立磁增强MRI检查。扫描序列包括频率选择脂肪抑制及非脂肪抑制ASTE T2WI、True FISP T2WI、频率选择脂肪抑制FLASH T1WI。比较增强前后T2WI及T2WI病灶及肝脏的信噪比（SNR）及对比噪声比（CNR）;观察增强前后病灶数量及形态;结合MR平扫及增强MRI表现进行定性诊断。结果 菲立磁增强T2WI及T2WI肝脏信号强度较平扫明显下降,病灶与肝脏的CNR较平扫明显提高,差异具有统计学意义。结论 菲立磁增强T2WI及T2WI可明显提高肝脏实性占位性病灶的检出率。菲立磁增强T1WI在脏局灶性病变的定性诊断中具有潜在价值,有待于进一步开发与研究。     

常规MRI联合MR脑血管成像在围产期脑后部可逆性脑病综合征中的应用研究

目的：探讨常规磁共振成像（MRI）联合MR脑血管成像在围产期脑后部可逆性脑病综合征（PRES）诊断和鉴别诊断中的应用价值。方法：5例围产期PRES患者,平均年龄为26.5岁,且均于起病后2 d内行常规MRI和MR脑血管成像,MR脑血管成像包括MR脑动脉成像（MRA）和MR脑静脉成像（MRV）。结果：病变均累及双侧顶枕叶,另累及额叶2例,基底节区2例,桥脑1例,病变占位效应不明显。病变主要位于皮层下白质,其中1例累及皮质。病变T1WI呈低、等信号,T2WI及液体衰减反转恢复序列（FLAIR）呈高信号。3例磁共振扩散加权成像（DWI）呈等信号,表观扩散系数（ADC）图为高信号,另2例部分病变DWI为高或稍高信号。增强扫描以上病变未见明确强化,MRA、MRV未见明确异常。结论：围产期RPES的MRI表现较具特征性,常规MRI联合MR脑血管成像有助于本病的早期诊断和鉴别诊断。     

神经纤维瘤病I型的MRI研究

目的：回顾神经纤维瘤病I型（NF1）患者MRI表现，分析MR扫描序列及其诊断价值，以建立合适的MR成像方案，为NF1影像诊断提供有价值的依据。方法：对30例临床确诊为NF1患者采用本组MR成像方案进行扫描，主要包括：轴面SE序列T2WI；平扫矢状面SE脉冲序列T1WI；增强轴面或矢状面SE脉冲序列T1WI；轴面或冠状面液体衰减反转恢复（FLAIR）序列，同时分析病变的发病部位、数目、形态、信号的变化和病变的强化情况等。结果：MRI可见下列3种表现：（1）多发性脑内错构瘤：30例中25例在SE脉冲序列T2WI和FlAIR脉冲序列见高信号病灶，病灶主要位于苍白球、小脑和脑干。另外，25例中20例可见海马回、海马旁回等区晕状高信号改变。（2）视通道或下丘脑胶质瘤：视神经、视交叉增粗、扭曲；视交叉或下丘脑肿块，SE脉冲序列T2WI和FlAIR序列表现为不规则分叶状混杂信号肿块，在增强SE脉冲序列T1WI有明显不规则强化。（3）脊柱多发性神经纤维瘤：SE脉冲序列T2WI和脂肪抑制短时反转恢复（STIR）序列显示高信号沿脊神经分布的多发性肿瘤。结论：MRI能够作为1种 常规的影像检查方法对NF1患者进行诊断和追踪。本组MR成像方案能较好地显示NF1的多发性或多灶性病变。     

3.0 T MRI不同脉冲序列对胰腺疾病的诊断价值

目的 探讨MRI检查不同脉冲序列对胰腺病变的诊断价值。方法 对87例临床怀疑胰腺病变的病人应用3.0 T MR设备进行检查,扫描序列包括双回波T1WI（同相位与反相位成像）、脂肪抑制T1WI（T1WI+FS）、脂肪抑制T2WI (T2WI+FS)、磁共振胆胰管水成像（MRCP）、快速多层面扰相梯度回波(FSPGR)动态增强扫描。由2名放射科医师分析不同脉冲序列的MRI所见。结果 正常胰腺15例,急性胰腺炎27例,慢性胰腺炎30例,胰腺癌15例。T1WI+FS显示胰腺形态与信号最佳,正常胰腺呈稍高信号。在双回波T1WI上,胰腺与周围组织对比度降低。胰腺病变在T1WI上表现为低信号50例,T2WI+FS显示胰周渗出性病变34例。MRCP显示胰管扩张35例,胆管扩张20例,双管征9例。快速扰相梯度回波（FSPGR）动态增强显示胰腺癌13例,肿块在动脉期表现为相对低信号,延迟期轻度强化,周围血管受侵2例。结论 合理应用MR扫描序列有助于提高胰腺病变的诊断效能。     

MR小视野扩散加权成像在肾上腺结节中的应用价值

【摘要】目的：探讨MR小视野扩散加权成像（rFOV DWI）在肾上腺结节中的应用价值。方法：纳入24例肾上腺占位患者,所有患者均行常规平扫、全视野扩散加权成像（fFOV DWI）及rFOV DWI扫描（b=0、800s/mm2）。由2位影像诊断医师通过5分法对DWI图像质量进行主观评分,利用eADC软件测定肾上腺结节的ADC值。结果：rFOV DWI图像主观评分为（4.68±0.65）分,高于fFOV DWI图像［（3.79±0.59）分］,差异有统计学意义（Z=-4.329,P＜0.01）。fFOV DWI及rFOV DWI测得的腺瘤组与非腺瘤组ADC值差异均无统计学意义（P值均＞0.05）。结论：rFOV DWI可获得更高的组织分辨力,清晰显示病变与正常肾上腺的关系,为肾上腺小结节及增生性病变的诊断提供更多依据,ADC值在肾上腺结节定性诊断方面价值有限。     

肾上腺疾病的磁共振影像诊断

本对37例共43个肾上腺病灶的MRI作定性和定量分析，结果表明，（1）MR可清晰显示大于1.0cm的病灶及其与周围结构的关系；（2）MR对腺瘤与转移瘤的鉴别有较大的帮助，T2WI腺瘤类似于肝脏的信号强度，转移瘤与脂肪的信号强度相似；（3）嗜铬细胞瘤的MRI有特异性，T2WI呈明显高信号，45%见散在点状短T2低信号区。     

Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses

PURPOSE: To retrospectively compare the accuracy of delayed enhanced computed tomography (CT) and chemical shift magnetic resonance (MR) imaging for characterizing hyperattenuating adrenal masses at CT, with either follow-up imaging or pathologic review as the reference standard. MATERIALS AND METHODS: The institutional review board approved this retrospective study with a waiver of patient informed consent. Forty-three hyperattenuating adrenal masses (>10 HU) on unenhanced CT images were found in 34 patients (23 men and 11 women; mean age, 52.7 years) by reviewing radiologic reports. These lesions were retrospectively analyzed with delayed enhanced CT and chemical shift MR. The diagnostic accuracy of CT by using absolute percentage loss of enhancement (PLE) and relative PLE and of chemical shift MR by using adrenal-to-spleen ratio (ASR) or signal intensity index (SII) were obtained to determine which modality was more accurate for lipid-poor adenoma. For CT, an adenoma was diagnosed if a mass had an absolute PLE greater than 60% and a relative PLE greater than 40%. For MR, an adenoma was diagnosed if a mass had an ASR of 0.71 or an SII greater than 16.5%. McNemar test was used to compare diagnostic performance of CT and MR. RESULTS: Hyperattenuating adrenal masses included 37 adenomas and six nonadenomas. The sensitivity, specificity, and accuracy for adenoma at CT were 97% (36 of 37), 100% (six of six), and 98% (42 of 43), respectively, and at MR were 86% (32 of 37), 50% (three of six), and 49% (21 of 43), respectively. CT helped confirm five more adenomas and three more metastatic tumors than did MR. However, there was no significant difference for diagnostic accuracy between these two imaging modalities (P>.05) CONCLUSION: Delayed enhanced CT can characterize additional hyperattenuating adrenal masses that cannot be characterized with chemical shift MR.     

Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role?

PURPOSE: To evaluate chemical shift magnetic resonance (MR) imaging for the characterization of hyperattenuating adrenal masses. MATERIALS AND METHODS: Adrenal MR images obtained from January 1998 to February 2003 were reviewed. Patients were excluded if they did not undergo unenhanced computed tomography or did not have an adrenal mass with attenuation higher than 10 HU, adequate follow-up, or pathologic diagnosis for use as a reference standard. A diagnosis of adenoma required at least 24 weeks of stability on images. Thirty-eight masses in 36 patients were identified (27 adenomas, nine metastases, one adrenocortical oncocytoma, and one pheochromocytoma). Signal intensity (SI) decrease between in-phase and opposed-phase MR images was measured for the entire mass and normalized to the renal parenchymal SI. In 21 of 36 (58%) patients, dual-echo single-breath-hold MR imaging was used to eliminate misregistration. RESULTS: The attenuation of 61% (23 of 38) of all masses and 70% (19 of 27) of adenomas was 10-30 HU. With a threshold of 20% SI decrease, the sensitivity of chemical shift MR imaging for hyperattenuating adenoma was 67% (18 of 27 masses). When considering masses with attenuation of 10-30 HU, the sensitivity for adenoma was 89% (17 of 19 masses) and remained reasonable at 75% (six of eight masses) for adenomas with attenuation of 20-30 HU. Only one adenoma with attenuation higher than 30 HU had SI decrease of more than 20%. Specificity for diagnosis of adenoma was 100% (11 of 11). CONCLUSION: In certain circumstances, chemical shift MR imaging is a reasonable second imaging test for further characterization of a hyperattenuating adrenal mass.     

Magnetic resonance imaging of the adrenal gland]

Adrenal imaging was performed using magnetic resonance (MR) was in 100 patients who had no clinical or biochemical evidence of adrenal abnormality and in 19 patients with 24 adrenal lesions (adenoma in 5, hyperplasia in 2, metastasis in 5, (lung cancer in 1, hepatoma in 4) adrenal cancer in 1, pheochromocytoma in 3, neuroblastoma in 3). Normal adrenal glands showed intermediate intensity between muscle and liver, and were detected in over 90% of cases on T1-weighted images (T1-weighted SE, inversion recovery). Adenomas and hyperplasias had the same intensity as normal glands. Medullary masses showed extreme hyperintensity on T2-weighted images and could be differentiated from cortical masses. Neuroblastomas were detected as hyperintense tumors with intratumoral hemorrhage and necrosis on T2-weighted MR images. Metastatic adrenal tumors from lung cancer were hyperintense on T2-weighted images, while metastasis from hepatoma showed low intensity on the same pulse sequence. In diagnosing adrenal metastasis, we must compare and contrast the tumor intensity and structure with those of the primary lesions. MR is considered a useful modality in characterizing adrenal tissue.     

Cross-sectional imaging work-up of adrenal masses

Advances in medical imaging with current cross-section modalities enable non-invasive characterization of adrenal lesions. Computed tomography (CT) provides characterization with its non-contrast and wash-out features. Magnetic resonance imaging (MRI) is helpful in further characterization using chemical shift imaging (CSI) and MR spectroscopy. For differentiating between benign and malignant masses, positron emission tomography (PET) imaging is useful with its qualitative analysis, as well as its ability to detect the presence of extra-adrenal metastases in cancer patients. The work-up for an indeterminate adrenal mass includes evaluation with a non-contrast CT. If a lesion is less than 10 Hounsfield Units on a non-contrast CT, it is a benign lipid-rich adenoma and no further work-up is required. For the indeterminate adrenal masses, a lipid-poor adenoma can be differentiated from a metastasis utilizing CT wash-out features. Also, MRI is beneficial with CSI and MR spectroscopy. If a mass remains indeterminate, PET imaging may be of use, in which benign lesions demonstrate low or no fluorodeoxyglucose activity. In the few cases in which adrenal lesions remain indeterminate, surgical sampling such as percutaneous biopsy can be performed.     

Discriminatory power of MRI for differentiation of adrenal non-adenomas vs adenomas evaluated by means of ROC analysis: Can biopsy be obviated?

The purpose of our study was to evaluate the discriminatory power of MRI in high-field magnet (1.5 T) for differentiation of adrenal non-adenomas vs adenomas assessing the following parameters separately and in combination: mean diameter of adrenal mass; previously described and new ratios as well as index calculated from signal intensity (SI) on SE T2-weighted images, chemical shift imaging (CSI), and Gd-DTPA-enhanced dynamic studies. One hundred eight adrenal masses (36 non-hyperfunctioning adenomas, 27 pheochromocytomas, 23 aldosterone-secreting adenomas, 20 malignant masses and 2 cortisol-secreting adenomas) in 95 patients were evaluated with SE sequences, CSI and Gd-DTPA dynamic studies. Indices and ratios of SI for all examined MRI methods were calculated and examined retrospectively for significance of differences between the groups with calculation of sensitivity and specificity. Receiver operating characteristics (ROC) analysis of calculated parameters in combination was performed. The multifactorial analysis of all four parameters, including size of the tumor, T2_liver index, CSI ratio reflecting lipid content in the tumor and Wo_max/last ratio reflecting maximal washout of contrast agent from the tumor had 100 % sensitivity and 100 % specificity in characterization of adrenal non-adenoma. The best performance of combination of mean tumor diameter with single MRI SI parameter was achieved in combination with T2_liver index for all adrenal masses (area under ROC 0.987) and CSI ratio for non-hyperfunctioning adrenal masses (area under ROC 0.991). Magnetic resonance imaging enables sensitive and specific diagnosis of adrenal non-adenoma. Received: 18 June 1998; Revised: 11 January 1999; Accepted: 5 May 1999     

Diagnostic accuracy of chemical-shift MR imaging to differentiate between adrenal adenomas and non adenoma adrenal lesions

PURPOSE: The objective of this study was to evaluate the diagnostic accuracy of chemical-shift (CS) magnetic resonance (MR) imaging in the differential diagnosis of adenoma and nonadenoma adrenal masses. MATERIALS AND METHODS: We enrolled 36 patients (9 men, 27 women, mean age 51.3+14.4 years) with unilateral (n=31) or bilateral (n=5) adrenal masses incidentally discovered during imaging examinations [ultrasound (US), computed tomography (CT)] performed for other indications. A total of 41 adrenal lesions were evaluated (mean diameter 3.0+2.2 cm). Histology (n=19), biopsy (n=3) or clinical-imaging follow-up (n=19) demonstrated 29 adenomas, five pheochromocytomas, three cysts and four carcinomas. MR imaging was performed using the following breath-hold sequences: T1-fast field echo (FFE) [repetition time (TR)/echo time (TE)=236/4.6 ms], T2-turbo spin echo-single shot (TSE-SSh) (TR/TE=831/80 ms), T1-DUAL-FFE (TR=236, double TE=4.6/2.3 ms in phase and out of phase) and T1-FFE after gadolinium-DTPA (Gd). Axial and coronal imaging planes were used, with a slice thickness of 3-5 mm. MR images were qualitatively assessed for signal intensity of the adrenal mass relative to the liver on T1, T2, CS and T1-Gd scans; diagnostic criteria for adenomas were isointensity or hypointensity on both T1 and T2 scans, out-of-phase CS signal loss and mild transient enhancement after Gd. RESULTS: Analysis of T1-T2 signal intensity showed diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 80%, 72%, 100%, 100% and 60%, respectively. In contrast, analysis of CS and T1-Gd signal intensity showed diagnostic accuracy, sensitivity, specificity, PPV and NPV for both sequences of 93%, 90% (p<0.05 vs. T1-T2 analysis), 100%, 100% and 80% (p<0.05 vs. T1-T2 analysis), respectively. CONCLUSIONS: CS MR imaging significantly improves characterization of adrenal masses compared with conventional T1-T2-weighted images, providing accuracy similar to that of the T1 sequence after Gd. Therefore, the CS sequence is strongly recommended for MR study of adrenal masses, and its use might obviate the need for Gd administration.     

MR evaluation of adrenal masses at 1.5 T

We retrospectively studied the value of MR imaging at 1.5 T to distinguish between nonadenomatous (n = 17) and adenomatous (n = 15) adrenal masses on the basis of (1) signal-intensity ratios on T1- and T2-weighted spin-echo images, (2) T2 relaxation times, and (3) T2 relaxation-time ratios. Univariate and then multivariate logistic regression were applied to these quantitative parameters to determine which of these best discriminated nonadenomas from adenomas, and whether or not more than one of these parameters improved the prediction. The adrenal mass/liver signal-intensity ratio on T2-weighted spin-echo images could not be used to differentiate nonadenomas from adenomas. Adrenal mass/fat signal-intensity ratios on T2-weighted spin-echo images, adrenal/liver T2 relaxation-time ratios, and adrenal mass T2 relaxation times were best for distinguishing nonadenomas from adenomas. By using a T2 value of greater than 61 msec, the true-positive ratio/false-positive ratio of differentiating nonadenomas from adenomas was 100%/20%; at greater than 82 msec, it was 64%/0.06%. The adrenal mass/fat signal-intensity ratios on T2-weighted spin-echo images and the adrenal/liver T2 relaxation-time ratios showed similar inherent discriminatory capacity. Overlap remains despite the use of these parameters. On the basis of this preliminary information, we conclude that MR has merit for the characterization of adrenal masses at 1.5 T. T2 relaxation time of the adrenal mass shows the greatest promise for discriminating nonadenomas from adenomas.     

Testicular adrenal rest tissue in congenital adrenal hyperplasia: comparison of MR imaging and sonographic findings

OBJECTIVE: The purpose of our study was to describe the MR features of testicular adrenal rest tissue in patients with congenital adrenal hyperplasia and to compare the usefulness of MR imaging with that of sonography for the detection of testicular adrenal rest tissue. SUBJECTS AND METHODS: Nineteen patients with congenital adrenal hyperplasia underwent MR imaging and gray-scale and color Doppler sonography of the testicles during the same visit to our institution. Findings were compared. RESULTS: MR features of testicular adrenal rest tissue included the following: isointensity (71% of the masses) and slight hyperintensity (29% of the masses) relative to normal testicular tissue on T1-weighted images; hypointensity relative to normal testicular tissue on T2-weighted images (100% of the masses); and diffuse enhancement on contrast-enhanced T1-weighted images (85% of the masses). MR imaging and sonography revealed the testicular lesions equally well. Eleven (58%) of 19 patients had normal findings on MR imaging and sonography. Eight (42%) of 19 patients had 14 intratesticular masses detected by both imaging techniques. CONCLUSION: MR imaging and sonography are equally useful in the detection of testicular adrenal rest tissue. Because sonography is more accessible to most institutions and is less expensive, it is the imaging technique of choice for the detection of testicular adrenal rest tissue.     

Adrenal masses: quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas

PURPOSE: To quantify fat content in adrenal lesions with double-echo chemical shift magnetic resonance (MR) imaging in a phantom study and to differentiate adrenal adenomas from other adrenal masses by assessing fat content in a clinical study. MATERIALS AND METHODS: The study consisted of two parts: a phantom study and a clinical study. To explore the effect of the T1 value on in- and opposed-phase MR images of fat-containing tissues, phantom models with various proportions of fat and gadopentetate dimeglumine concentrations were implemented. Signal intensity (SI) indexes ([SI in-phase - SI opposed-phase]/SI in-phase) were calculated with double-echo fast low-angle shot (FLASH) MR imaging. In the clinical study, 23 patients with 28 adrenal masses (16 adrenal adenomas, nine adrenal metastases, and three pheochromocytomas) underwent double-echo FLASH MR imaging, and SI indexes were calculated. RESULTS: SI index reached a maximum of 0.87 at 53% fat fraction for gadopentetate dimeglumine concentration at 0.5 mmol/L as the simulated T1 of the adrenal mass. The SI indexes of the adrenal adenomas, adrenal metastases, and pheochromocytomas, respectively, were 0.36, -0.15, and -0.07, and estimated fat fraction from the phantom study was 26.5%, 0%, and 0%. All adrenal adenomas contained fat on double-echo FLASH images. There was no overlap in SI index between adenomas and other tumors. CONCLUSION: Preliminary experience indicates that quantitative measurement of the fat fraction of adrenal masses is possible with the double-echo chemical shift FLASH technique and allows for differentiating adrenal adenomas from other adrenal masses.